internship project at cepheid ab 2016 for a doctoral...
TRANSCRIPT
Internship project at Cepheid AB 2016 for a doctoral student from Karolinska Institute
About Cepheid, GeneXpert Systems and Xpert Tests Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy‐to‐use molecular systems and tests. By automating highly complex and time‐consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic‐based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.
With more than 9,800 systems in 182 countries, the GeneXpert System is the world’s most popular molecular diagnostics’ instrument. The GeneXpert System’s modular configuration means that the system is the most scalable available, offering the ability to perform from one to eighty Xpert tests at the same time. As a result, the GeneXpert System meets the throughput requirements of customers of all sizes ‐ from lower volume point‐of‐care settings to higher volume reference laboratories. GeneXpert Systems run proprietary Xpert test cartridges. The Xpert test menu spans healthcare‐associated infections, sexual health, critical infectious disease, and oncology, and today offers 23 tests outside the US, and 19 tests in the US.
For more information, visit www.cepheid.com.
Latent TB Project More than 3 700 GeneXpert systems have been placed in 108 tuberculosis (TB) high‐burden countries, and more than 15 million Xpert MTB‐RIF tests have been shipped to date. As a complement to the Xpert MTB‐RIF test, a potential new test (Xpert Latent TB) should be able to identify persons with latent tuberculosis infection (LTBI), who do not have Active TB disease (i. e. not positive by Xpert MTB‐RIF or bacteria culture), but are latently infected and at risk of progression to disease. The WHO post‐2015 global TB strategy, which aims to reduce global TB incidence by 90% before 2035, encourages screening for LTBI in TB contacts and selected high‐risk groups with provision of appropriate treatment for infected individuals.
Before development of an Xpert cartridge assay for LTBI testing can start, a target validation study is needed. Currently, candidate mRNA targets and normalizing markers are being evaluated on clinical blood samples from TB‐ and LTBI patients, as well as from normal healthy control donors. When an appropriate set of biomarkers has been identified, different Mycobacterium tuberculosis antigens for immunostimulation of blood will also be evaluated as part of this Pre‐Development project.
Internship Project 2016 This Internship Project involves two parts;
(i) Assist in our ongoing target validation study, where multiple cytokine‐ and IFN‐gamma induced chemokine candidate markers from M. tuberculosis‐recognizing T‐cells in immunostimulated whole blood are studied. This work requires overnight immunostimulation of clinical whole blood samples followed by lysis/stabilization of the blood and banking the samples at ‐80 °C for analysis by RT‐PCR. Approx. 2‐4 patients per week are expected to be enrolled in the study.
(ii) As part of the Latent TB Pre‐Development project, we need to identify M. tuberculosis antigens (recombinant protein or peptide pool), suitable for immunostimulation of blood from individuals suspected to be infected by M. tuberculosis. Factors to consider include HIV/TB co‐infection, young children, immunosuppression, and possibility to distinguish LTBI from Active TB disease. The work will involve searches in literature‐ as well as patent databases, and will result in a summary of the findings in an internal report.
Candidate Profile Basic knowledge in immunology, and preferably experience from working with antigenic stimulation of T cells.
Period for this Internship Project is June‐July 2016.
Contacts Malin Nygren, PhD, Pre Concept Specialist, Research and Development Department of Research and Development, Cepheid AB, PO Box 1427, SE‐171 27 SOLNA, Sweden +46 8 6843 7145 [email protected] Per Grufman, PhD, Executive Director, Research and Development Department of Research and Development, Cepheid AB, PO Box 1427, SE‐171 27 SOLNA, Sweden +46 8 6843 7106 [email protected]
Full-time or Part-time Creative Marketing Internship
Job Location:
Stockholm Job Description:
If you are passionate about helping a small but growing consultancy in the Anglo Nordic Life Science sector by providing international business development a LucyJRobertshaw internship offers a unique opportunity for professional growth and learning. We are looking for a capable intern who is able to hit the ground running, that is entrepreneurial, innovative and a strategic thinker with excellent communications and analytical skills. Interns are team players and have a strong commitment to our clients. They also bring a sense of humour and enjoy having fun. Objectives of the program: This internship offers you the experience of understanding how a virtual consultancy works in the UK and Sweden and the opportunity to:
Gain exposure to how the business world works
Create an interactive Anglo Nordic cluster map
Attend networking events with possible travel to the UK
Hone their writing, research and strategic thinking skills
Work with high-profile clients on current projects
Job Requirements:
Interns must have a good level of the English language to be able to work closely with LucyJRobertshaw staff to assist in the day to day role. Interns are provided hands-on experience meaningfully contributing to client goals.
Starting date: 4th April 2016
PhD student secondment (1 month, fully financed KI) Project description Description of organisation The Swedish Research Council (SRC; Vetenskapsrådet) is the largest Swedish funding agency for basic research at Swedish universities, colleges and institutes. The SRC also functions as research policy advisor to the Government and works on the long-term expansion of knowledge within analysis, strategy and the monitoring of research and research funding (see www.vr.se). Description of project The work will involve taking part in an analysis of collected data on the applications and awarded grants within Medicine/Health at SRC which are classified into specific medical or health research areas according to the Health Research Classification System (HRCS, see http://www.hrcsonline.net/ for more information). The aim is to compile data from 2010-2014 since the last analysis performed 2009 to analyse annual and accumulated data of:
• Number of applications/awards in different medicine/health research areas;
• Success rates and size of grants in different medicine/health research areas;
• Correllation analysis between success rates and SRC peer review groups; • Correllation analysis between success rates and disease burden expressed
as the disability-adjusted life year (DALY). Requested qualifications of applicant
• Strong analytical skills, knowledge of Excel and statistical analysis • Fluency in English required whilst knowledge of Swedish is an advantage
Project period May-June or September Contact person Patriq Fagerstedt, Senior Research Officer Unit for Science Policy Advice, Department of Science Policy, SRC 08-54644246, [email protected]
Datum Diarienummer
2016-02-19 Diarienummer Handläggare
Patriq Fagerstedt
1 (1)
Doktorandpraktik (1 månad)- för 1 person Projektbeskrivning Beskrivning av företaget Statens beredning för medicinsk och social utvärdering (SBU) är en statlig myndighet med uppdrag att utvärdera metoder som används i vården och socialtjänsten, både etablerade och nya, ur ett samlat medicinskt, ekonomiskt, etiskt och socialt perspektiv. SBU arbetar med olika typer av produkter, såsom utvärderingsrapporter i olika omfattning, kommentarer av utländska systematiska rapporter (SBU Kommenterar), kartläggning av vetenskapliga kunskapsluckor, eller ger svar på riktade frågor från beslutsfattare i vården (SBU:s Upplysningstjänst). Beskrivning av praktikprojekt Praktiken skulle utföras inom ramen för SBU Upplysningstjänst. Upplysningstjänsten är till för vårdens beslutsfattare – personer i ledande befattning, verksamhetschefer, sektionschefer och områdesansvariga. Upplysningstjänsten kan bidra med kunskapsunderlag inför strategiska beslut. Beslutet kan till exempel gälla om en ny metod ska införas eller någon äldre metod fasas ut.
Praktiken avser att ge kunskaper i systematisk informationssökning enligt PICO. Dessutom kommer doktoranden att få granska och sammanställa information samt skriftligt besvara en upplysningstjänstfråga. Önskad kravprofil på doktoranden/forskaren • Goda kunskaper inom det medicinska området/medicinsk terminologi • Goda kunskaper i vetenskaplig metodik • Goda skriftliga kunskaper i svenska och engelska • Kunskaper i litteratursökning i medicinska databaser
Datum för praktikperiod (endast fram till den 18 juni). Kontaktpersoner på företaget för ytterligare information Jessica Dagerhamn, Projektledare SBU:s Upplysningstjänst, telefon 08-412 32 65 [email protected] eller Jan Liliemark, Avdelningschef för avdelningen för utvärderingar och Upplysningstjänst telefon: 08-412 32 71 [email protected]
an easy way to stay healthy for everyone!
Description
HealthiHabits is a health transformer dedicated to improving the life of individuals with a chronic
disease. Our unique social analytics platform empowers people to achieve a sustainable lifestyle
through instant and personalized support. This helps them to make better decisions in their daily
activities and gain control of their medical condition. Through innovative technology, we are
becoming a valuable partner to key players in the health care system. We are an ambitious startup in
digital health and committed to a bold vision: to connect everyone to the world’s healthiest
behaviors and create the easiest way to be healthy.
Project Description
HealthiHabits offers the opportunity of a 1 month internship. The incumbent will generate a
scientific literature study and scientific evaluation around digital interventions on chronic diseases.
Scaled against the incumbent’s background and interest, aspects of technology can play an
important role in this project. We offer the opportunity to be involved in and contribute to core
aspects of this venture. You will be working with a dynamic, international and highly experienced
team. Due to the nature of this project, we follow an agile methodology. Certain aspects of our
project become more important than currently anticipated, and may influence this project’s focus.
Candidate’s Profile
PhD student with a background in conducting research within chronic disease and have a
background, or an interest in developing skills around data science and social as well as expanding
his/her network outside the university environment. We are looking for self starters that are keen to
take our vision a step.
Contact Details
The mentor of this project is Christian Guttmann. He is is an entrepreneurially driven technology
leader with strong research and communication skills. His focus is on creating value in Digital Health
Care. At BT, IBM, HP and successful startups, he led innovation teams/projects using analytics and
AI, and social/mobile/IoT technology. He creates high-impact systems, patents, and scientific
publications. He enjoys working with great teams and in productive partnerships.
Christian Guttmann, Founder, [email protected], 0707419945
Start
Flexible: May-August
0
• Project Work Opportunity
This is an opportunity for a PhD student at KI to get practical industry experience within the growing and highly important field of Real World Evidence and big data. IMS Health, a world leading Consultancy Company within the Real World Evidence, Health Economics and Outcome Research fields, wants to engage with young, smart and driven academics as a way to collaborate with and to find the most talented people for the future.
• Project Description
In this project the overall objective is to perform practical Real World Evidence work and epidemiological research with data from healthcare registries and electronic medical records. You will get the opportunity to contribute to several projects that are in different phases, you will perform desk research, preparations for data extractions, analytical/statistical work, and/or science writing tasks such as study protocols, statistical analysis plans, study reports, and scientific publications.
• Project duration: 1 month
• Details on the Project
Depending on the background of the applicant and status of the ongoing research activities, the work can be focusing on either of the following tasks:
1. Preparing for research projects involving the following activities
Desk research to gather evidence and literature required for protocol writing, ethical applications, study design, etc
Drafting of study protocol
Preparation of ethical application
IMS Health_Project Description for Internship
Project Work Opportunity IMS Health
1
2. Data extraction and analysis
Preparation of registry data applications
Field work activities related to the extraction of data from electronic medical records
Data management (cleaning, categorization of free text information, etc)
Drafting of statistical analysis plan
Participating in statistical analysis of registry based data
3. Dissemination
Drafting of clinical study report
Preparation for scientific publications (literature search, drafting texts, etc)
Contributing to dissemination material (abstracts, posters, etc)
The applicant will get the chance to take an active role in different phases of ongoing research projects, typically large, retrospective, studies involving datasets gathered from national registries, disease databases, hospitals, primary care units, etc within the fields of oncology, infectious disease, respiratory disease, cardiovascular disease, etc. There are opportunities to perform activities tailored to prior experience and know-how as well as to learn new things and broaden the therapeutic knowledge.
In the end of the project you will get the opportunity to present and discuss the project work with a broader Real World Evidence team in the Nordics.
• Contact Persons at IMS Health Sr Consultant, RWES: Julia Rockberg, PhD, E-mail: [email protected] Human Resources: Simona Staaff-Lindgren, E-mail: [email protected]
IMS Health_Project Description for Internship
Project Work Opportunity IMS Health
15 February 2016
Affibody AB
Gunnar Asplunds Allé 24, SE-171 63 Solna, Sweden Tel +46 8 59 88 38 00
www.affibody.com Org. No. 556665-6913
Internship project: Establishment of cellular based assays for the analysis of anti-migraine drugs
Background
Affibody AB is a company developing Affibody molecules for therapeutic, diagnostic and biotechnological applications. Affibody molecules are small and robust affinity ligands based on the three-helical-bundle Z domain. Monoclonal antibodies are routinely used as therapeutic agents for the treatment of diseases such as breast cancer, leukemia, asthma, arthritis, and different autoimmune diseases. Important advances have been made over the past decade to improve the engineering technologies, safety and efficacy of the first generation of therapeutic antibodies. These developments, along with a greater understanding of the immunomodulatory properties of antibodies, have paved the way for the next generation of new and improved antibody-based drugs for the treatment of human diseases.
Migraine is among the most prevalent neurological disorders worldwide. A broad array of analgesics can be prescribed for acute treatment of migraine attacks, but there is still a large unmet need for an effective anti-migraine treatment. The drugs available to ease acute pain are associated with poor efficacy and pronounced side effects. Through the proprietary Affibody® technology platform we are able to provide an opportunity to develop small, effective and safe affinity ligands to treat migraine.
Project plan
This project aims to establish a cellular based assay for the evaluation of a new type of anti-migraine drugs. The student will use established cell based in vitro assays and explore methods to analyze the inhibitory potential of several different anti-migraine constructs. The laboratory techniques that will be used in this project are; SDS-PAGE, cell cultivation, cAMP analysis, ELISA and AlphaLisa. The laboratory work and results will be documented in our electronic lab notebook system Biovia® Notebook.
The project will be 4 weeks full time, during the preferred time period of week 17-23. Requirements
A thorough knowledge in cell based assays.
Hands on experience of cellular based assays and physical characterisation of proteins.
High standard regarding details and accurate laboratory work.
Fluent Swedish and English, both orally and written.
KI_Affibody_Internhip_vt2016.docx 2 (2)
Co
nfid
en
tial
Nice to have (but not a requirement)
Good knowledge regarding migraine pathophysiology.
Experience with electronic lab notebooks.
Contact person
Lindvi Gudmundsdotter, PhD
Senior Scientist, In vitro Pharmacology
Affibody AB
Gunnar Asplunds Allé 24 , 171 63 Solna
Phone +46 70 456 05 26
www.affibody.com
The project generation phase: literature overview of potential new targets
Medivir:
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseases and oncology.
Medivir markets pharmaceutical products in the Nordics. Our product range today comprises fifteen prescription pharmaceuticals within a number of different therapeutic areas. Our overall goal is to give people a better quality of life by alleviating symptoms and curing diseases with these products.
The project:
We are continuously evaluating the literature, searching for new potential targets that fit with our technology platform with the aim to develop new cancer therapies. In this search we are evaluating the available literature to assess both the association between the target and the disease and the tractability of target. To do this we are scrutinizing available literature to assess whether a potential target has a strong link to a mechanism involved in cancer, whether there is clinical data to support a role for the target in cancer, e.g. mutations or overexpression patterns correlating with specific cancer types, outcome or resistance to available treatments and whether there is pre-clinical data to support a molecular mechanism whereby the target is involved in cancer. With regards to target tractability, we are assessing whether the target is a suitable candidate for drug discovery from a chemical perspective, from an assay perspective and from a biophysical perspective.
In this project you will search and analyze the literature on a number of potential candidates within a particular target class for their potential as drug discovery targets, with regards to target validity and target tractability. You will be supervised by scientists with experience of evaluating potential targets from a drug discovery perspective and will get the chance to learn about the drug discovery process from target validation to the pre-clinical phase.
Contact details: [email protected]
Start date: to be discussed
The project generation phase: target validation by siRNA-mediated knock-down of potential new targets and analysis of their effect in normal versus cancer cells.
Medivir:
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseasesand oncology.
Medivir markets pharmaceutical products in the Nordics. Our product range today comprises fifteen prescription pharmaceuticals within a number of different therapeutic areas. Our overall goal is to give people a better quality of life by alleviating symptoms and curing diseases with these products.
The project:
When bringing new projects into our drug discovery pipeline, we need to perform a thorough experimental assessment of their potential as targets for new cancer therapies. This means we will replicate literature findings to confirm the results and thoroughly test the hypothesis in vitro for how inhibition of a particular target would be beneficial as a cancer therapy. Most often we will use siRNA as a means of abolishing the activity of the target of interest.
In this project you will be part of a team of biologists investigating the validity of a potential target for our drug discovery pipeline, assessing the effect of knock-down of the target on the proliferation and viability of different cancer cell lines. The project will include optimization of transfection, validation of antibodies, western blot analysis, proliferation assays and viability assays. You will be supervised by scientists with experience of evaluating potential targets from a drug discovery perspective and will get the chance to learn about the drug discovery process from target validation to the pre-clinical phase.
This project requires good knowledge of cell culture techniques, transfection and western blot analysis.
Contact details: [email protected]
Start date: to be discussed
The early drug discovery process: establishing/validating a biochemical assay and screening of small molecules within a drug discovery project
Medivir:
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseases and oncology.
Medivir markets pharmaceutical products in the Nordics. Our product range today comprises fifteen prescription pharmaceuticals within a number of different therapeutic areas. Our overall goal is to give people a better quality of life by alleviating symptoms and curing diseases with these products.
The project:
The aim of the drug discovery process is to find new molecules with good potency against our target of interest, with high selectivity and good ADME properties. In the early phases we build our knowledge of which aspects of the molecules’ structures are important for biological activity by screening thousands of molecules in biochemical assays. Each biochemical assay is a simplified version of the activity we are aiming to target, for example the enzyme the project is looking to inhibit as a means of treating cancer.
In this project you will be part of a team of enzymologists establishing and validating a biochemical assay. This work involves optimizing buffer conditions, enzyme and substrate concentrations, incubation times, and protocols and validating the stability and reproducibility of the assay by screening large number of compounds. You will be supervised by scientists with long experience of drug discovery and biochemical assay development and screening, and will get the chance to learn about the drug discovery process from target validation to the pre-clinical phase.
This project requires good knowledge and experience of laboratory work.
Contact details: [email protected]
Start date: to be discussed
Evaluation and development of computational models for drug discovery
Medivir:
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseases and oncology.
Medivir markets pharmaceutical products in the Nordics. Our product range today comprises fifteen prescription pharmaceuticals within a number of different therapeutic areas. Our overall goal is to give people a better quality of life by alleviating symptoms and curing diseases with these products.
The project:
A wide range of computational methods are used extensively in pharmaceutical research. In early drug discovery, compounds are usually prioritized for synthesis, not only by considering primary activity, but also by taking predictions of physiochemical and safety properties into account. As such properties are important for all drugs, a wealth of historical data is publically and commercially available. Hence, empirical predictive methods, using state-of-the-art machine learning, can often be used to develop a mathematical model describing the relationship between the molecular structure and the property. Such models are referred to as Quantitative Structure Activity Relationships (QSARs).
In general, empirical models interpolate well, but extrapolate poorly. Hence, predictions for chemical structures differing significantly from the structures used in developing the model, will be poorly predicted. Consequently, for any successful predictive model application, the prediction needs to be complemented by a quantification of the reliability of the prediction. At the very least this is achieved by comparing predictions and experimental values for a set of compounds similar to the ones that will be predicted.
Medivir is looking to improve its capabilities in predicting physiochemical and safety properties. As part of this initiative, the publically and commercially available datasets and models need to be evaluated on chemical structures relevant to the research of Medivir. This project entails a literature search to identify relevant models and datasets, an evaluation of existing models by prediction of properties of internal Medivir compounds and potentially development of novel QSAR models. Jejunum membrane permeability and a range of safety endpoints such as mitochondrial toxicity, hepatoxicity, phospholipidosis and cytotoxicity are prioritized.
Contact details: [email protected]
Start date: to be discussed
The company - Focus on patients
We focus on developing innovative medicines and diagnostic tests that help patients live longer, better lives. Two-thirds of all diseases are either still not treated adequately or not treated at all. This medical need is enormous and better diagnostics and medicines can make a huge difference to the lives of millions of patients and their relatives.
Project:
As the leading company within oncology and personalized healthcare we are now moving into the next phase of innovation where it is now technically possible to connect the patient's unique disease biology to different drugs during all phases of the disease in real time and a strong development regarding the role of immunology in cancer.
In order to facilitate this complex new environment there is a need to optimize resource allocation and bring the new technologies together, where testing, treatments and outcome data will be used in a “state of art” manner. To accomplish all this there is a need for a Center of Excellence.
The objective of this project is to investigate and map specific needs and resources necessary for the development of a Center of Excellence within Immuno-therapy in cancer.
Profile: PhD student from Karolinska Institute interested in the project above
Contact: [email protected], phone: 070-612 12 18
Starting date: Flexible
Perimed AB Datavägen 9A, SE-175 43 Järfälla, Sweden
Phone: +46-8-580 119 90, Fax: +46-8-580 100 28 E-mail: [email protected] Website: www.perimed-instruments.com
VAT-Number: SE556196690301, Registered Office, Stockholm, Sweden
Marketing of diagnostic equipment for vascular assessment
Perimed AB: Perimed AB, established in Sweden in 1981, is a global provider of diagnostic solutions for patients suffering from peripheral vascular disease, a disease severely affecting the outcome of for example diabetic foot ulcers. Perimed AB has about 50 employees at the headquarter located in Järfälla and an additional 20 in subsidiaries in USA, UK, France, Italy, Germany and China. Perimed AB develops, produces and sells the PeriFlux 6000 System which offers a unique possibility to combine macrovascular and microvascular measurements in the limb obtaining diagnoses of peripheral arterial disease and assessment of the wound healing potential. The instrument allows simultaneous measurements of ankle- and toe pressures and transcutaneous oxygen (tcpO2) measurements. An examination with the PeriFlux 6000 System will speed up the workflow, still securing accurate diagnosis that will aid in making the correct clinical decisions. This will result in reduced complications for the patients, for example unnecessary amputations, and cut hospital costs. Internship project: The candidate will search for, and analyze literature and relevant clinical studies including toe and ankle pressures and tcpO2 measurements. The challenge of this project is to present the techniques, tests and reference values together with selected publications in a short, informative and eye-catching report aimed to clinicians with little knowledge about this type of vascular assessments. The purpose is to highlight the importance of above mentioned examinations, the advantage of our specific techniques, and cost savings achieved by performing these examinations in the long run. For more information about Perimed, please visit www.perimed-instruments.com Requirements: Experience in writing reviews and designing award-winning scientific posters. Interest in the circulatory system. Fluency in English. Timeline: Flexible, Q2 2016 is preferred. Contact: Karin Larsson Product and Application Specialist [email protected] 073 – 270 52 22
Research plan GE Healthcare; Biacore influenza assay 4 weeks, preferably during the spring 2016 Tentative title: Biacore quantitation of influenza virus Background GE Healthcare Life Sciences provides medical and analytical technologies including services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE is specialized in drug discovery, biopharmaceutical manufacturing technologies, such as SPR biosensors (Biacore) used to monitor bio-molecular interactions. With more than 25-years in the label-free interaction analysis market, GE today can provide expertise in Biacore applications across industry and academic research. Determining influenza virus haemagglutinin (HA) concentration is critical for the final formulation of the influenza vaccine and for manufacturing process development. HA concentration is today commonly determined by single radial immunodiffusion assay (SRID), having a number of disadvantages. An analytical method using Biacore T200 has been developed with significant advantages over SRID1. However both these methods still require standard reagents which take up to 3 months to obtain each season. A feasibility study exploring a new idea regarding quantitation without a standard has been performed, but more literature studies and Biacore experiments are needed to learn if this approach has any chance of success. Purpose of the project Increase our knowledge regarding the potential for this new approach to be successful, through literature studies and running Biacore experiments. Profile An interest in Biacore technology, lab work and literature studies. An advantage is a general experience of different detergents, as dissolving influenza vaccine may be included in the project. Depending on the results this work may be confidential, limiting publication. Contact info: Åsa Frostell, Senior Scientist, R&D, GE Healthcare, Björkgatan 30, 751 84 Uppsala. 018-67 57 50, 073 033 0346, [email protected] 1Estmer Nilsson C, Abbas S, Bennemo M, Larsson A, Hämäläinen M D, Frostell-Karlsson Å. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine, 2010, 28, 759–766.
GE Healthcare, Confidential 160216 Åsa Frostell
1
National review of sepsis management for BIO-X project Bugsee
The company: Uppsala BIO is an independent and not-for-profit actor working to stimulate growth in the life science sector. Uppsala BIO is STUNS's, the Foundation for Collaboration between the Universities in Uppsala, Industry and Society, operational arm for working with the life science sector and its development. We bring together the universities, companies, healthcare, and society to secure the development of the sector's international competitiveness. Uppsala BIO is located in Origo (Dag Hammarskjölds väg 10B), in Uppsala Science Park. We share offices with other innovation support organizations, such as Uppsala Innovation Centre, Uppsala University Innovation and SLU Holding. Uppsala BIO operates in the Stockholm-Uppsala Region.
Background: One of Uppsala BIO’s core activities is BIO-X. BIO-X is Sweden’s only complete early-stage life science commercialization program using project calls to select and fund potential solutions to specific, fully-defined healthcare and society needs. In a BIO-X theme from 2013 solutions for hospital acquired infections were called for and three project that were granted have since then been working on developing their solution. One of the projects, Bugsee, is devoted to early detection of sepsis, this to improve the outcome for the patient and provide the staff with a powerful diagnostic tool to enable that correct and specific treatment is set in as early as possible to save lives and limit antibiotics-resistance. Sepsis is the body's overwhelming and life-threatening response to infection which can lead to tissue damage, organ failure, and death. In this context sepsis due to bacteria in the bloodstream is considered. In order to build a business plan, the project needs to understand how sepsis is practically managed throughout Sweden today. One way to collect such information is by means of a survey, and address what the needs are, how a quick sepsis diagnosis will fit and bring benefit in the care system, on a national level.
The information gathered in the survey will need to be analysed, packaged and communicated. For further information on Uppsala BIO see the following links: http://uppsalabio.com
Project Description:
The objective of the internship is to plan, execute and report a survey within Swedish healthcare with regards to management of sepsis and to test if a new product concept is beneficial for the care system and for the patient. Initial health economy calculations may be included, depending on survey results. The survey will be based on interviews (F2F and/or by telephone) with care professionals at different hospitals in Sweden. Deliverables from the internship is a report of the survey and a summary presentation in PowerPoint format. This project will start with development of the survey questionnaire, identifying relevant hospitals and individuals (nurses & physicians) to interview. After the interview phase a report will be completed.
Dates: a suitable time for the project is mid April to mid June. We prefer the candidate to help us full time for one month but we are open for discussion.
Suitable profile: We are searching a person interested in market research and communication. You need to know how to structure survey data into a report and work with Microsoft Power Point. You should be working independently, be able to search information and see connections outside the obvious. A big advantage if you are interested in market research, questionnaire design and have good communications skills. This project will give you a great insight into market research, development of MedTech products and product fit into health care as well as valuable contacts for the future.
Contact person: Erik Olaisson BIO-X Coach & Project Manager Uppsala BIO Uppsala Science Park SE-751 83 Uppsala
